Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 31;61(43):17059-17067.
doi: 10.1021/acs.inorgchem.2c01992. Epub 2022 Oct 17.

Bn2DT3A, a Chelator for 68Ga Positron Emission Tomography: Hydroxide Coordination Increases Biological Stability of [68Ga][Ga(Bn2DT3A)(OH)]

Affiliations

Bn2DT3A, a Chelator for 68Ga Positron Emission Tomography: Hydroxide Coordination Increases Biological Stability of [68Ga][Ga(Bn2DT3A)(OH)]

Thomas W Price et al. Inorg Chem. .

Abstract

The chelator Bn2DT3A was used to produce a novel 68Ga complex for positron emission tomography (PET). Unusually, this system is stabilized by a coordinated hydroxide in aqueous solutions above pH 5, which confers sufficient stability for it to be used for PET. Bn2DT3A complexes Ga3+ in a hexadentate manner, forming a mer-mer complex with log K([Ga(Bn2DT3A)]) = 18.25. Above pH 5, the hydroxide ion coordinates the Ga3+ ion following dissociation of a coordinated amine. Bn2DT3A radiolabeling displayed a pH-dependent speciation, with [68Ga][Ga(Bn2DT3A)(OH)]- being formed above pH 5 and efficiently radiolabeled at pH 7.4. Surprisingly, [68Ga][Ga(Bn2DT3A)(OH)]- was found to show an increased stability in vitro (for over 2 h in fetal bovine serum) compared to [68Ga][Ga(Bn2DT3A)]. The biodistribution of [68Ga][Ga(Bn2DT3A)(OH)]- in healthy rats showed rapid clearance and excretion via the kidneys, with no uptake seen in the lungs or bones.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Scheme 1
Scheme 1. Synthesis of Bn2DT3A and Subsequent Complexation of Ga3+. (a) (i) EtOH, Benzaldehyde, Reflux. (ii) NaBH4, 0 °C. (b) MeCN, Na2CO3, tert-Butyl Bromoacetate, 60 °C. (c) DCM, TFA. 0 °C to RT. (d) H2O, GaCl3, pH 4, Reflux
Figure 1
Figure 1
Molecular structure of [Ga(Bn2DT3A)] determined by X-ray crystallography. Hydrogen atoms have been omitted for clarity. Colors: gallium (pale brown); carbon (gray); nitrogen (blue); oxygen (red).
Figure 2
Figure 2
Speciation of Ga3+ in solution with Bn2DT3A. (T = 25 °C, I = 0.1 M NMe4Cl, [Bn2DT3A] = 4 mM, [Ga3+] = 2 mM).
Figure 3
Figure 3
Calculated energy of water molecule (blue) and hydroxide anion (green) interacting with [Ga(Bn2DT3A)] at various Ga–O distances.
Figure 4
Figure 4
(A) Radio-HPLC of [68Ga][Ga(Bn2DT3A)(OH)] following semipreparative HPLC purification. (B) Stability of [68Ga][Ga(Bn2DT3A)(OH)] to FBS assessed by radio-TLC. (i) Isolated species. (ii) After 30 min incubation in FBS. (iii) After 120 min incubation. (C) Radio-HPLC of [68Ga][Ga(Bn2DT3A)] following semipreparative HPLC purification. (D) Stability of [68Ga][Ga(Bn2DT3A)] to FBS assessed by radio-TLC. (i) Isolated species. (ii) After 30 min incubation in FBS. (E) Radio-TLC of [68Ga][GaCl3] incubated with FBS.
Figure 5
Figure 5
Effect of common reaction parameters on the radiolabeled products of [68Ga][GaCl3] and Bn2DT3A as assessed by radio-HPLC. (A) Effect of pH. [Bn2DT3A] = 100 μM. T = 25 °C. I = 0.1 M NaxH3–xPO4. t = 15 min. (B) Effect of ligand concentration. T = 25 °C. I = PBS. pH = 7.4. t = 15 min. (C) Effect of temperature. [Bn2DT3A] = 100 μM. I = PBS. pH = 7.4. t = 5 min. (D) Effect of reaction time. [Bn2DT3A] = 100 μM. T = 25 °C. I = PBS. pH = 7.4.
Figure 6
Figure 6
PET scans of healthy Sprague-Dawley rats injected with either [68Ga][Ga(Bn2DT3A)(OH)] (top two rows) or [68Ga][Ga(Citrate)] (bottom two rows) at indicated time points. Subsequent CT scan provided for co-registration of signal.

References

    1. Basu S.; Kwee T. C.; Surti S.; Akin E. A.; Yoo D.; Alavi A. Fundamentals of PET and PET/CT Imaging. Ann. N. Y. Acad. Sci. 2011, 1228, 1–18. 10.1111/j.1749-6632.2011.06077.x. - DOI - PubMed
    1. Jackson J. A.; Hungnes I. N.; Ma M. T.; Rivas C. Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations and Future Challenges. Bioconjugate Chem. 2020, 31, 483–491. 10.1021/acs.bioconjchem.0c00015. - DOI - PubMed
    1. Bartholomä M. D.; Louie A. S.; Valliant J. F.; Zubieta J. Technetium and Gallium Derived Radiopharmaceuticals: Comparing and Contrasting the Chemistry of Two Important Radiometals for the Molecular Imaging Era. Chem. Rev. 2010, 110, 2903–2920. 10.1021/cr1000755. - DOI - PubMed
    1. Velikyan I. 68Ga-Based Radiopharmaceuticals: Production and Application Relationship. Molecules 2015, 20, 12913–12943. 10.3390/molecules200712913. - DOI - PMC - PubMed
    1. Blower J. E.; Cooper M. S.; Imberti C.; Ma M. T.; Marshall C.; Young J. D.; Blower P. J.. The Radiopharmaceutical Chemistry of the Radionuclides of Gallium and Indium. In Radiopharmaceutical Chemistry; Lewis J. S., Windhorst A. D., Zeglis B. M., Eds.; Springer, Cham: Cham, 2019; pp. 255–271, 10.1007/978-3-319-98947-1_14. - DOI